Janux Therapeutics is a pre-commercial biotech with a platform-first strategy, evidenced by R&D expenses averaging $30M per quarter against sporadic collaboration revenue that swung from $10.3M in 2026Q2 to zero in 2025Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.34+28.2% vs -$0.47 | $9M+15.7% vs $8M |
Q3 2026 Aug 6, 2026 | -$0.35-39.3% vs -$0.25 | $10M-46.2% vs $19M |
Q2 2026 May 7, 2026 | -$0.39+25.0% vs -$0.52 | $4M-14.3% vs $4M |
Q1 2026 Feb 26, 2026 | -$0.51+21.5% vs -$0.65 | $8M+9356.0% vs $83,333 |
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update. “During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007,” said David Campbell, Ph.D., President a.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, November 9, 2026, at 8:30 a.m. ET.David Campbell, Ph.D., President and Chief Executive Officer, will present initial clinical data from the Phase 1 single-ascending-dose study of JANX011 in healthy volunteers. The presentation will review safety, pharmacokinetics and pharmacodynamic.
Zai Lab (NASDAQ: ZLAB - Get Free Report) and Janux Therapeutics (NASDAQ: JANX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. Analyst Ratings This is a breakdown of recent
Benchmark JANX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Janux Therapeutics, Inc. (JANX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.63 | $1.08B | -11.14 | -5.55% | -428.74% | -10.68% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $21.50 | $3.5B | -26.04 | 48.29% | -229.92% | -25.74% | — | |
| $192.28 | $40.88B | -22.10 | — | -946.82% | -91.93% | — |
Janux Therapeutics, Inc. (JANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Janux Therapeutics, Inc. (JANX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 23, 2026·SEC
Jun 12, 2026·SEC
Get notified when JANX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Janux Therapeutics, Inc. (JANX) stock FAQ — growth, dividends, profitability & financials explained
Janux Therapeutics, Inc. (JANX) reported $23.3M in revenue over the trailing twelve months. Revenue was $10.0M in fiscal year 2025.
Janux Therapeutics, Inc. (JANX) grew revenue by 132.9% over the trailing twelve months, compared with the twelve months before.
No. Janux Therapeutics, Inc. (JANX) reported a net loss of $99.8M over the trailing twelve months.
Janux Therapeutics, Inc. (JANX) had a return on equity (ROE) of -10.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Janux Therapeutics, Inc. (JANX) had negative free cash flow of $54.2M over the trailing twelve months.
